Abbott Laboratories
$97.50Change from previous close: +0.84%Absolute change: +$0.81
At a glance
- Revenue growth
- +5.67%
- 2025 vs 2024
- Net income growth
- −51.32%
- 2025 vs 2024
- Net margin
- 14.7%
- 2024: 31.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 2,488 | 1,315 | 3,315 | 2,787 | 2,047 | 1,417 | 2,868 | 2,705 | 1,960 | 1,025 | 3,038 | 1,877 |
| Depreciation and amortization | 1,060 | 803 | 792 | 791 | 777 | 756 | 807 | 801 | 805 | 805 | 813 | 824 |
| Capital expenditure | -497 | -399 | -689 | -496 | -502 | -484 | -720 | -556 | -533 | -398 | -755 | -560 |
| Investing cash flow | -673 | -20,324 | -913 | -457 | -582 | -470 | -866 | -594 | -453 | -425 | -824 | -634 |
| Financing cash flow | -3,518 | 17,313 | -1,397 | -1,760 | -1,097 | -2,055 | -1,861 | -1,576 | -791 | -1,176 | -2,052 | -2,340 |
| Dividends paid | -1,102 | -1,098 | -1,030 | -1,031 | -1,029 | -1,026 | -958 | -960 | -961 | -957 | -888 | -888 |
| Share repurchases | -1,045 | -180 | -302 | -305 | -6.0 | -280 | -315 | -751 | -3.0 | -226 | -259 | -2.0 |
| Debt issued | 31.0 | 19,891 | 2.0 | 0.0 | 2.0 | 1.0 | 1.0 | 1.0 | 221 | — | 22.0 | — |
| Debt repaid | -1,405 | -1,416 | -72.0 | -493 | -17.0 | -1,037 | -614 | 42.0 | -61.0 | -127 | -961 | -1,506 |
| Effect of exchange rates | 4.0 | -23.0 | 6.0 | -10.0 | 51.0 | 24.0 | -83.0 | 36.0 | -13.0 | -36.0 | 25.0 | -29.0 |
| Net change in cash | -1,699 | -1,719 | 1,011 | 560 | 419 | -1,084 | 58.0 | 571 | 703 | -612 | 187 | -1,126 |
| Free cash flow | 1,991 | 916 | 2,626 | 2,291 | 1,545 | 933 | 2,148 | 2,149 | 1,427 | 627 | 2,283 | 1,317 |
| Levered free cash flow | 1,819 | 1,155 | 1,688 | 2,103 | 1,272 | 1,103 | 1,467 | 2,013 | 1,429 | 702 | 2,177 | 1,028 |